Breakthrough Recovery Formula and Antioxidant
Bio-BDMC™30, is a patented curcumin extract with one of the highest levels of BDMC (bisdemethoxycurcumin) available in the world today. In a standard
curcumin extract, BDMC exists in extremely low concentrations – between 0.5% to 1.5%. When it is increased to 30% (BDM30), it provides a breakthrough in inflammatory therapy at the genetic and subcellular level. Research suggests that BDM30 targets and neutralizes a key protein in the nucleus of cells that switches off the production of inflammatory proteins and is more precisely targeted as a curcumin therapy. BDMC inhibits NF-kB and MSK1 to combat inflammation from two targets. Regular curcumin only inhibits NF-kB.
Curcumin extracts typically deliver a curcuminoid proportion as: diferuloylmethane (curcumin I) 75–80%;demethoxycurcumin (DMC — curcumin II) 9-12%; and bisdemethoxycurcumin (BDMC — curcumin III) 0.2–3%.
Regular curcumin extracts (even the 95% variation) maximally delivers 3% of this BDMC activity and therefore cannot inhibit a key protein (MSK1) that
regulates inflammatory cytokine transcription (generation). The patented Curcumin BDMC30™ is engineered to deliver a minimum 30%
concentration of these curcuminoids.
Relief from pain, swelling and other common ailments associated with systemic inflammation. Patented pharmacology delivered by a novel research-supported mechanism that is recently peer-reviewed and published.
